179 related articles for article (PubMed ID: 33461420)
21. Effectiveness of fecal immunochemical testing in reducing colorectal cancer mortality from the One Million Taiwanese Screening Program.
Chiu HM; Chen SL; Yen AM; Chiu SY; Fann JC; Lee YC; Pan SL; Wu MS; Liao CS; Chen HH; Koong SL; Chiou ST
Cancer; 2015 Sep; 121(18):3221-9. PubMed ID: 25995082
[TBL] [Abstract][Full Text] [Related]
22. Participant-Related Risk Factors for False-Positive and False-Negative Fecal Immunochemical Tests in Colorectal Cancer Screening: Systematic Review and Meta-Analysis.
de Klerk CM; Vendrig LM; Bossuyt PM; Dekker E
Am J Gastroenterol; 2018 Dec; 113(12):1778-1787. PubMed ID: 30158713
[TBL] [Abstract][Full Text] [Related]
23. Divergent Long-Term Detection Rates of Proximal and Distal Advanced Neoplasia in Fecal Immunochemical Test Screening Programs: A Retrospective Cohort Study.
Zorzi M; Hassan C; Capodaglio G; Narne E; Turrin A; Baracco M; Dal Cin A; Fiore A; Martin G; Repici A; Rex D; Rugge M
Ann Intern Med; 2018 Nov; 169(9):602-609. PubMed ID: 30285055
[TBL] [Abstract][Full Text] [Related]
24. Colonoscopy later than 270 days in a fecal immunochemical test-based population screening program is associated with higher prevalence of colorectal cancer.
Zorzi M; Hassan C; Capodaglio G; Baracco M; Antonelli G; Bovo E; Rugge M
Endoscopy; 2020 Oct; 52(10):871-876. PubMed ID: 32356282
[TBL] [Abstract][Full Text] [Related]
25. Impact of a higher fecal immunochemistry test cut-off on pathology detected in subsequent rounds of a colorectal screening program.
Gibson DJ; Mooney T; Mooney J; Mulcahy HE; O'Donoghue D
Gastrointest Endosc; 2019 Mar; 89(3):518-522. PubMed ID: 30142350
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and cost-effectiveness of fecal immunochemical test versus colonoscopy in colorectal cancer screening: a systematic review and meta-analysis.
Zhong GC; Sun WP; Wan L; Hu JJ; Hao FB
Gastrointest Endosc; 2020 Mar; 91(3):684-697.e15. PubMed ID: 31790657
[TBL] [Abstract][Full Text] [Related]
27. Interval cancers after negative immunochemical test compared to screen and non-responders' detected cancers in Slovenian colorectal cancer screening programme.
Mlakar DN; Bric TK; Škrjanec AL; Krajc M
Radiol Oncol; 2018 Jul; 52(4):413-421. PubMed ID: 30511936
[TBL] [Abstract][Full Text] [Related]
28. Risk of colorectal cancer in patients with positive results of fecal immunochemical test performed within 5 years since the last colonoscopy.
Jung YS; Lee J; Moon CM
Korean J Intern Med; 2021 Sep; 36(5):1083-1091. PubMed ID: 34134468
[TBL] [Abstract][Full Text] [Related]
29. Colorectal cancer detection in an asymptomatic population: fecal immunochemical test for hemoglobin vs. fecal M2-type pyruvate kinase.
Caviglia GP; Cabianca L; Fagoonee S; Gili FM
Biochem Med (Zagreb); 2016; 26(1):114-20. PubMed ID: 26981025
[TBL] [Abstract][Full Text] [Related]
30. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know.
Tinmouth J; Lansdorp-Vogelaar I; Allison JE
Gut; 2015 Aug; 64(8):1327-37. PubMed ID: 26041750
[TBL] [Abstract][Full Text] [Related]
31. A combination of clinical risk stratification and fecal immunochemical test results to prioritize colonoscopy screening in asymptomatic participants.
Aniwan S; Rerknimitr R; Kongkam P; Wisedopas N; Ponuthai Y; Chaithongrat S; Kullavanijaya P
Gastrointest Endosc; 2015 Mar; 81(3):719-27. PubMed ID: 25708760
[TBL] [Abstract][Full Text] [Related]
32. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
[TBL] [Abstract][Full Text] [Related]
33. Gender-specific cut-offs in colorectal cancer screening with FIT: Increased compliance and equal positivity rate.
Blom J; Löwbeer C; Elfström KM; Sventelius M; Öhman D; Saraste D; Törnberg S
J Med Screen; 2019 Jun; 26(2):92-97. PubMed ID: 30336730
[TBL] [Abstract][Full Text] [Related]
34. Factors associated with false-positive and false-negative fecal immunochemical test results for colorectal cancer screening.
Wong MC; Ching JY; Chan VC; Lam TY; Luk AK; Ng SS; Sung JJ
Gastrointest Endosc; 2015 Mar; 81(3):596-607. PubMed ID: 25293827
[TBL] [Abstract][Full Text] [Related]
35. Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults.
Sharma T
Public Health; 2020 May; 182():70-76. PubMed ID: 32179290
[TBL] [Abstract][Full Text] [Related]
36. Extending Colorectal Cancer Screening to Persons Aged 40 to 49 Years With Immunochemical Fecal Occult Blood Test: A Prospective Cohort Study of 513,283 Individuals.
Chen CH; Tsai MK; Wen CP
J Clin Gastroenterol; 2016 Oct; 50(9):761-8. PubMed ID: 26905605
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness analysis of colonoscopy and fecal immunochemical testing for colorectal cancer screening in China.
Ren Y; Zhao M; Zhou D; Xing Q; Gong F; Tang W
Front Public Health; 2022; 10():952378. PubMed ID: 36033786
[TBL] [Abstract][Full Text] [Related]
38. A population-based comparison of immunochemical fecal occult blood tests for colorectal cancer screening.
Raginel T; Puvinel J; Ferrand O; Bouvier V; Levillain R; Ruiz A; Lantieri O; Launoy G; Guittet L
Gastroenterology; 2013 May; 144(5):918-25. PubMed ID: 23376426
[TBL] [Abstract][Full Text] [Related]
39. The value of hypersensitivity quantitative fecal immunochemical test in early colorectal cancer detection.
Jiang L; Xu F; Feng W; Fu C; Zhou C
Postgrad Med J; 2024 Feb; 100(1181):135-141. PubMed ID: 38055911
[TBL] [Abstract][Full Text] [Related]
40. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
Smith A; Young GP; Cole SR; Bampton P
Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
